Economic burden of chronic pain in Alberta, Canada.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
21
04
2022
accepted:
23
07
2022
entrez:
12
8
2022
pubmed:
13
8
2022
medline:
17
8
2022
Statut:
epublish
Résumé
Although chronic pain (CP) is common, little is known about its economic burden in Alberta, Canada. To estimate incremental (as compared to the general population or people without CP) societal (healthcare and lost productivity) costs of CP in Alberta. We applied the prevalence estimated from the Canadian Community Health Survey data to the population retrieved from the Statistics Canada to estimate the number of people with CP in Alberta in 2019. We analyzed the Alberta Health administrative databases to estimate the healthcare costs of person with CP. Finally, we multiplied the number of people with the cost per person. The prevalence of any CP was 20.1% and of activity-preventing CP was 14.5% among people aged > = 12 years. Incremental cost per person with CP per year was CA$2,217 for healthcare services (among people aged > = 12 years) and CA$8,412 for productivity losses (among people aged 18-64 years). Of the healthcare cost, prescription drugs accounted for the largest share (32.8%), followed by inpatient services (31.0%), outpatient services (13.1%), physician services (9.8%), other services (7.4%), and diagnostic imaging (5.8%). Provincially, total incremental cost of CP ranges from CA$1.2 to 1.7 billion for healthcare services (6% to 8% of total provincial health expenditure); and CA$3.4 to 4.7 billion for productivity losses. Considering costs for long-term care services, the total societal cost of CP in Alberta was CA$6.3 to 8.3 billion per year, reflecting 2.0% to 2.7% of Alberta's GDP. Interventions improving CP prevention and management to reduce this substantial economic burden are urgently needed.
Sections du résumé
BACKGROUND
Although chronic pain (CP) is common, little is known about its economic burden in Alberta, Canada.
AIMS
To estimate incremental (as compared to the general population or people without CP) societal (healthcare and lost productivity) costs of CP in Alberta.
METHODS
We applied the prevalence estimated from the Canadian Community Health Survey data to the population retrieved from the Statistics Canada to estimate the number of people with CP in Alberta in 2019. We analyzed the Alberta Health administrative databases to estimate the healthcare costs of person with CP. Finally, we multiplied the number of people with the cost per person.
RESULTS
The prevalence of any CP was 20.1% and of activity-preventing CP was 14.5% among people aged > = 12 years. Incremental cost per person with CP per year was CA$2,217 for healthcare services (among people aged > = 12 years) and CA$8,412 for productivity losses (among people aged 18-64 years). Of the healthcare cost, prescription drugs accounted for the largest share (32.8%), followed by inpatient services (31.0%), outpatient services (13.1%), physician services (9.8%), other services (7.4%), and diagnostic imaging (5.8%). Provincially, total incremental cost of CP ranges from CA$1.2 to 1.7 billion for healthcare services (6% to 8% of total provincial health expenditure); and CA$3.4 to 4.7 billion for productivity losses. Considering costs for long-term care services, the total societal cost of CP in Alberta was CA$6.3 to 8.3 billion per year, reflecting 2.0% to 2.7% of Alberta's GDP.
CONCLUSIONS
Interventions improving CP prevention and management to reduce this substantial economic burden are urgently needed.
Identifiants
pubmed: 35960750
doi: 10.1371/journal.pone.0272638
pii: PONE-D-22-11788
pmc: PMC9374207
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0272638Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
BMC Public Health. 2013 Dec 24;13:1229
pubmed: 24365383
Fam Pract. 2017 Nov 16;34(6):656-661
pubmed: 28444208
Clin J Pain. 2020 Jun;36(6):472-479
pubmed: 32205516
J Popul Ther Clin Pharmacol. 2014;21(3):e421-30
pubmed: 25658807
Med J Aust. 2003 Jul 21;179(2):84-7
pubmed: 12864718
Pain Res Manag. 2011 Nov-Dec;16(6):445-50
pubmed: 22184555
Pain. 2016 Aug;157(8):1626-33
pubmed: 26989805
J Pain. 2012 Aug;13(8):715-24
pubmed: 22607834